All Blogs
Jul 09, 2025
siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile
WVE-007 is a GalNAc-conjugated small interfering RNA (siRNA) designed to target the messenger RNA of the INHBE gene, which encodes the liver-derived protein Activin E. Activin E suppresses fat breakdown (lipolysis) by acting directly on adipose tissue. By silencing INHBE, WVE-007 aims to remove this metabolic bloc...
Read More...
Jul 08, 2025
Merck’s WINREVAIR Granted FDA Priority Review for Pulmonary Arterial Hypertension; KalVista’s EKTERLY Approved by FDA as First Oral On-Demand Therapy for Hereditary Angioedema; Fujifilm’s FF-10832 Receives FDA Orphan Drug Designation for Biliary Tract Cancer; Mustang Bio’s MB-101 Granted FDA Orphan Drug Designation for Glioblastoma and Astrocytomas; Denali’s Tividenofusp Alfa Accepted for FDA Priority Review for Hunter Syndrome
Merck's WINREVAIR Gets FDA Priority Review for Pulmonary Arterial Hypertension Merck, also known as MSD outside the U.S. and Canada, announced that the FDA has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) for WINREVAIR (sotatercept-csrk). The application seeks to ...
Read More...
Jul 07, 2025
Current Pheochromocytomas and Paragangliomas Treatment Paradigms: Challenges and Opportunities
The metastatic pheochromocytomas and paragangliomas treatment landscape has seen notable progress alongside ongoing challenges. Although curative therapies are still lacking, patients benefit from a multidisciplinary care strategy involving debulking surgery, chemotherapy, tyrosine kinase inhibitors, immunotherapy,...
Read More...
Jul 04, 2025
GvHD Drugs Treatment Market Heats Up: 4 Late-Stage Therapies Poised to Redefine the Landscape
The GvHD drugs treatment landscape is undergoing a dynamic transformation, driven by a wave of innovation aimed at improving patient outcomes and quality of life. Once dominated by steroids and broad immunosuppressants, the field is now witnessing a surge in targeted therapies, cellular approaches, and novel biolog...
Read More...
Jul 03, 2025
FDA Clears Stryker’s Incompass Total Ankle System; Glaukos Receives EU MDR Approval for iStent infinite and Key MIGS Devices; STENTiT Announces First Patient Enrollment in Trial of Regenerative Stent for Limb Preservation; Autonomix Medical Treats First Patient in Next Phase (“PoC 2”) of Proof-of-Concept Clinical Trial; Getinge Expands Servo-C Ventilator Capabilities for Neonatal Care; Medtronic Partners With Philips to Advance Patient Monitoring Solutions
Stryker Received FDA Clearance for Incompass Total Ankle System On June 25, 2025, Stryker, a global leader in medical technologies, announced that the U.S. Food and Drug Administration (FDA) received 510(k) approval for its Incompass™ Total Ankle System. The implant is designed for patients suffering from ...
Read More...
Jul 02, 2025
How the Amniotic Membrane Market is Transforming Regenerative Healthcare Worldwide
The amniotic membrane market is revolutionizing healthcare by harnessing the natural healing power of the amniotic membrane, a thin placental layer renowned for its regenerative properties. This remarkable biomaterial is transforming treatments across specialties, particularly in amniotic membrane eye treatment, wh...
Read More...
Jul 01, 2025
Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis
FDA Approves Sobi’s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still’s Disease In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MA...
Read More...
Jun 30, 2025
Gilead YEZTUGO Makes History with First Twice-Yearly HIV Prevention Drug
Gilead Sciences has received a highly anticipated approval from the FDA for its long-acting HIV prevention injection, YEZTUGO (lenacapavir), marking a significant advancement in HIV prevention. On June 18, 2025, the FDA approved YEZTUGO, an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrE...
Read More...
Jun 27, 2025
The Spinal Cord Injury Treatment Landscape: Limited Progress, Immense Potential
Every year, thousands of lives are changed in an instant by spinal cord injuries—yet most people know surprisingly little about them. Spinal cord injury refers to the abrupt damage to the spinal cord's nerve tissue resulting from trauma, illness, or degenerative conditions. The impact can differ, often leading to u...
Read More...
Jun 26, 2025
GE HealthCare Receives FDA Approval for Expanded Vizamyl PET Imaging Indications in Alzheimer’s Disease Care; FDA Grants Approval to InspireMD’s CGuard® Prime for Carotid Artery Disease; AngioDynamics Launches RECOVER-AV Trial, Marking Milestone in AlphaVac F18⁸⁵ Development for PE Treatment; Tivic Health Concludes Study Optimizing Non-Invasive Vagus Nerve Stimulation Device for Personalized Therapy; Johnson & Johnson Introduces VOLT™ Plating System and ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM in the U.S.
GE HealthCare Announced that the FDA Approved Expanded Indications for Vizamyl Pet Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients On June 24, 2025, GE HealthCare announced that the U.S. Food and Drug Administration (FDA) approved an updated label for its PET i...
Read More...